Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    23020162 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting
Has Results
An Open-label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine + Lapatinib in Patients With HER2-positive Locally Advanced or Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Trastuzumab emtansine [Kadcyla];   Drug: Lapatinib;   Drug: Capecitabine

Indicates status has not been verified in more than two years